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Control of Glycolytic Flux by AMPK and 
p53-mediated Signaling Pathways in 
Tumor Cells Grown at Low pH
Introduction
Tumor cells grow in nutrient and oxygen deprived microenvironments 
and adapt to the suboptimal growth conditions by altering metabolic 
pathways. This adaptation process characteristically results in 
a tumor phenotype that displays upregulated Hif-1α anaerobic 
glycolysis, chronic acidification, reduced rate of overall protein 
synthesis, lower rate of cell proliferation and aggressive invasive 
characteristics. Most transplantable tumors exhibit a pHe of 6.7-
7.0; the DB-1 melanoma xenografts used here have a pHe=6.7. 
Understanding tumor cell reaction to the microenvironment is a 
critical factor in predicting the tumor response to radiotherapy. The 
glucose regulatory molecule, 6-Phosphofructo-2-Kinase/Fructose-2,6-
Biphosphatase Isoform-3 (PFKFB3), is a bifunctional enzyme central 
to glycolytic flux and downstream of the metabolic stress sensor 
AMP-activated protein kinase (AMPK), which we show activates an 
isoform of phosphofructokinase (PFK-2).
Methods
All techniques including the growth of the early passage DB-1 human 
melanoma and the U87 human glioma cells were standard and have 
been published.
Results
As hypothesized, our results demonstrated that growth at chronic 
pH 6.7 in air induced AMPK activation resulting in the upregulation 
of PFKFB3 and p53 and the downregulation of mammalian Target- 
Of-Rapamycin (mTOR) in both human tumor cell lines. Conversely, 
inhibition of AMPK resulted in downregulation of PFKFB3 
and inhibition of glycolysis. When PFKFB3 was transfected and 
overexpressed in DB-1 melanoma cells growing at pH 7.3, it induced 
a high rate of glycolysis and inhibited oxygen consumption, which 
could lead to tumor acidification and oxygenation. By contrast, cells 
growing at low pH did not display an increased rate of glycolysis 
after PFKFB3 expression because the level of the TP53-induced 
Glycolysis and Apoptosis Regulator (TIGAR) was increased. 
Cells growing at low pH also were resistant to radiation-induced 
apoptosis despite upregulation of p53. This was partially explained 
by the expression of the anti-apoptotic proteins, Bcl-2 and Bax; 
TIGAR’s ability to reduce  lactate production; and downregulation of 
mTOR. Conversely, growth at low pH blocked GSH production and 
reduced bioreduction.
Conclusion
These results indicate that growth at tumor-like low pH activates 
AMPK and PFKFB3 and induces a high glycolytic and apoptotic 
potential that is countered by TIGAR and anti-apoptotic proteins, 
respectively. Alterations in these pathways lead to predictable 
alterations in lactate and oxygen levels, mTOR, GSH and redox state, 
and response to radiation. The control of glycolysis can thus alter 
acidification, oxygenation and state of bioreduction and modify 
tumor cell death pathways. These metabolic pathways that respond 
to the microenvironment require incorporation in radiation 
treatment strategies.
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